(Q41922839)

28 October 2017

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial (English)

1 reference

28 October 2017

0 references

Orthoebolavirus zairense

0 references

phase I clinical trial

0 references

0 references

27

1 reference

14 October 2017

Henry M Staines

15

0 references

Peter Gottfried Kremsner

28

Peter G Kremsner

1 reference

28 October 2017

Martin Peter Grobusch

21

Martin P Grobusch

1 reference

28 October 2017

24

Benjamin Mordmüller

1 reference

28 October 2017

25

Bertrand Lell

1 reference

28 October 2017

Vasee Moorthy

18

0 references

Michael Ramharter

Michael Ramharter

23

0 references

Verena Krähling

10

Verena Krähling

1 reference

28 October 2017

19

Marie-Paule Kieny

1 reference

28 October 2017

22

Stephan Becker

1 reference

28 October 2017

Selidji T Agnandji

1

1 reference

28 October 2017

José F Fernandes

2

1 reference

28 October 2017

Emmanuel B Bache

3

1 reference

28 October 2017

Régis M Obiang Mba

4

1 reference

28 October 2017

Jessica S Brosnahan

5

1 reference

28 October 2017

Lumeka Kabwende

6

1 reference

28 October 2017

Paul Pitzinger

7

1 reference

28 October 2017

Pieter Staarink

8

1 reference

28 October 2017

Marguerite Massinga-Loembe

9

1 reference

28 October 2017

Nadine Biedenkopf

11

1 reference

28 October 2017

Sarah Katharina Fehling

12

1 reference

28 October 2017

Thomas Strecker

13

1 reference

28 October 2017

David J Clark

14

1 reference

28 October 2017

Jay W Hooper

16

1 reference

28 October 2017

Peter Silvera

17

1 reference

28 October 2017

Akim A Adegnika

20

1 reference

28 October 2017

VEBCON Consortium

26

1 reference

28 October 2017

language of work or name

English

0 references

publication date

6 October 2017

1 reference

28 October 2017

1 reference

28 October 2017

14

1 reference

28 October 2017

10

1 reference

28 October 2017

e1002402

1 reference

Creative Commons CC0 License

28 October 2017

start time

6 October 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted, dedicated to the public domain by copyright holder

0 references

cites work

Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

5 June 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

5 June 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Ebola vaccines in clinical trial: The promising candidates

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Clinical development of Ebola vaccines

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Ebola vaccine R&D: Filling the knowledge gaps.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, doub

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Global health security: the wider lessons from the west African Ebola virus disease epidemic

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Ebola vaccine--an urgent international priority

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Mapping the zoonotic niche of Ebola virus disease in Africa

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Reston ebolavirus in humans and animals in the Philippines: a review

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooué-Ivindo region, Northeastern Gabon, 1997.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5630143

Rubella vaccination in adult females

5 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28985239

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PMED.1002402

1 reference

28 October 2017

1 reference

28 October 2017

1 reference